z-logo
open-access-imgOpen Access
Long-term safety of subcutaneous immunotherapy with TO-204 in Japanese patients with house dust mite-induced allergic rhinitis and allergic bronchial asthma: Multicenter, open label clinical trial
Author(s) -
Takao Fujisawa,
Terufumi Shimoda,
Keisuke Masuyama,
Kimihiro Okubo,
Kohei Honda,
Mitsuhiro Okano,
Toshio Katsunuma,
Atsuo Urisu,
Yasuto Kondo,
Hiroshi Odajima,
Kazuyuki Kurihara,
Makoto Nagata,
Masami Taniguchi,
Shoichiro Taniuchi,
Satoru Doi,
Tomoshige Matsumoto,
Shoji Hashimoto,
Akihiko Tanaka,
Kensuke Natsui,
Nahoko Abe,
Hideki Ozaki
Publication year - 2017
Publication title -
allergology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.49
H-Index - 58
eISSN - 1440-1592
pISSN - 1323-8930
DOI - 10.1016/j.alit.2017.11.004
Subject(s) - medicine , asthma , adverse effect , allergy , house dust mite , anaphylaxis , clinical trial , anaphylactic shock , allergen immunotherapy , allergen , immunology
To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom